Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

I. Špička · SciRah

Researcher profile · Semantic Scholar

I. Špička

Share profile

I. Špička — researcher profile on SciRah

h-index: 46
Works: 391
Citations: 15K

Most-cited papers

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
T. Facon, M. Dimopoulos, X. Leleu, M. Beksaç +26 more
2024New England Journal of Medicine226 citations
Semantic Scholar
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma.
M. Dimopoulos, M. Beksaç, L. Pour, S. Delimpasi +18 more
2024New England Journal of Medicine153 citations
Semantic Scholar
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.
M. Dimopoulos, P. Voorhees, F. Schjesvold, Y. Cohen +32 more
2024New England Journal of Medicine79 citations
Semantic Scholar
Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study
Annie N. Cowan, F. Ferrari, Samuel S. Freeman, R. Redd +30 more
2023The Lancet Haematology70 citations Open access
Semantic Scholar
Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial
E. Zamagni, T. Silzle, I. Špička, S. Tahri +47 more
2024Blood34 citations
Semantic Scholar
Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis
P. Richardson, A. Perrot, J. S. Miguel, M. Beksaç +14 more
2024Haematologica31 citations Open access
Semantic Scholar
Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial.
K. Yong, T. Martin, M. Dimopoulos, J. Mikhael +17 more
2024The Lancet Haematology22 citations
Semantic Scholar
Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials
M. Mateos, Suzanne Trudel, H. Quach, P. Robak +32 more
2025Blood Advances21 citations Open access
Semantic Scholar
Isatuximab Subcutaneous by On-Body Delivery System vs Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 3 IRAKLIA Study.
S. Ailawadhi, I. Špička, Andrew Spencer, Jin Lu +28 more
2025Journal of Clinical Oncology14 citations Open access
Semantic Scholar
A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma
M. Dimopoulos, D. Coriu, S. Delimpasi, I. Špička +6 more
2024Blood Advances11 citations Open access
Semantic Scholar
Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ).
T. Facon, M. Dimopoulos, X. Leleu, M. Beksaç +16 more
2024Journal of Clinical Oncology11 citations Open access
Semantic Scholar
Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long‐term outcomes in the Phase 3 IKEMA study
T. Facon, P. Moreau, I. Špička, Kenshi Suzuki +8 more
2024Hematological Oncology9 citations Open access
Semantic Scholar
P-413 Characterization and Management of Ocular Events in Patients Treated With Belantamab Mafodotin Plus Pomalidomide and Dexamethasone in the DREAMM-8 Study
H. Quach, M. Dimopoulos, M. Beksaç, L. Pour +20 more
2024Clinical Lymphoma, Myeloma & Leukemia8 citations
Semantic Scholar
Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 Study.
A. Oriol, Roman Hájek, I. Špička, I. Sandhu +12 more
2024Clinical Lymphoma, Myeloma & Leukemia8 citations
Semantic Scholar
De-escalated Teclistamab dosing in relapsed/refractory multiple myeloma: Czech myeloma group real-world evidence analysis
M. Štork, J. Radocha, J. Mihályová, I. Špička +17 more
2025Annals of Hematology7 citations Open access
Semantic Scholar
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide
M. Beksaç, E. González García, S. Delimpasi, P. Robak +26 more
2024Blood7 citations
Semantic Scholar
Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies
P. Richardson, A. Perrot, J. Mikhael, T. Martin +14 more
2024Blood Cancer Journal7 citations Open access
Semantic Scholar
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Analyses of Minimal Residual Disease (MRD) Negativity Dynamics in the Phase 3 Imroz Study
R. Orlowski, M. Dimopoulos, X. Leleu, Zhuo-Gang Liu +16 more
2024Blood7 citations
Semantic Scholar
Updated Results From the Phase 3 DREAMM-8 Study of Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
M. Dimopoulos, M. Beksaç, L. Pour, S. Delimpasi +17 more
2025Clinical Lymphoma, Myeloma & Leukemia5 citations
Semantic Scholar
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial.
M. Dimopoulos, M. Beksaç, L. Pour, S. Delimpasi +23 more
2025The Lancet Haematology5 citations
Semantic Scholar
Deep responses and durable outcomes in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the Phase 3 dreamm-8 study
S. Trudel, M. Beksaç, L. Pour, S. Delimpasi +21 more
2025Blood4 citations
Semantic Scholar
Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO
Gurdeep Parmar, M. Capra, Fernanda Seguro, V. Hungria +19 more
2025Blood Cancer Journal4 citations Open access
Semantic Scholar
Erratum: Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.
S. Ailawadhi, I. Špička, Andrew Spencer, Jin Lu +28 more
2025Journal of Clinical Oncology4 citations
Semantic Scholar
The Impact of Isatuximab Regimens on Hypogammaglobulinemia Occurrence, Recovery, and Associated Infections in Patients with Relapsed/Refractory Multiple Myeloma
C. Rodriguez, A. Perrot, P. Richardson, T. Facon +10 more
2023Blood4 citations Open access
Semantic Scholar
BRIDGE (OP-107): A Phase 2 Pharmacokinetic Study of Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Impaired Renal Function.
L. Pour, S. Delimpasi, W. Legieć, J. Minařík +9 more
2026Clinical Lymphoma, Myeloma & Leukemia3 citations Open access
Semantic Scholar
Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma: dynamics of MRD negativity in the IMROZ study
R. Orlowski, M. Dimopoulos, X. Leleu, T. Facon +17 more
2026Blood3 citations Open access
Semantic Scholar
Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma Group
J. Minařík, L. Pour, V. Látal, T. Jelínek +14 more
2025BMC Cancer3 citations Open access
Semantic Scholar
Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age
Peter M. Voorhees, M. Dimopoulos, Y. Cohen, F. Schjesvold +35 more
2025Blood3 citations
Semantic Scholar
Evolution of Treatment Patterns and Survival Outcomes in European Patients with Multiple Myeloma from 2012-2023 through the Honeur Federated Data Network
M. Rückert, Guillaume Azarias, M. Garg, C. Bygrave +12 more
2024Blood3 citations
Semantic Scholar
Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study
F. Schjesvold, H. Ludwig, S. Delimpasi, P. Robak +14 more
2024Haematologica3 citations Open access
Semantic Scholar
Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study
M. Dimopoulos, P. Voorhees, F. Schjesvold, Y. Cohen +30 more
2024Blood3 citations
Semantic Scholar
Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
M. Merz, T. Jelínek, T. Pabst, R. Teipel +35 more
2026Blood Cancer Discovery2 citations Open access
Semantic Scholar
Isatuximab Subcutaneous via an on-body Delivery System versus Isatuximab Intravenous, Plus Pomalidomide and Dexamethasone, in Relapsed/Refractory Multiple Myeloma: The Randomized Phase 3 IRAKLIA Study
S. Ailawadhi, I. Špička, Jin Lu, A. Oriol +19 more
2025Clinical Lymphoma, Myeloma & Leukemia2 citations
Semantic Scholar
Patient Perspectives from the Phase 3 IRAKLIA Study of Isatuximab (Isa) Subcutaneous (SC) via On-Body Injector (OBI) vs Isa Intravenous (IV) in Relapsed/Refractory Multiple Myeloma (RRMM)
María-Victoria Mateos, I. Špička, Andrew Spencer, A. Oriol +16 more
2025Clinical Lymphoma, Myeloma & Leukemia2 citations
Semantic Scholar
Final Results of a Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
Barry Paul, J. Minařík, F. Cottini, C. Gasparetto +16 more
2025eJHaem2 citations Open access
Semantic Scholar
Baseline ocular conditions and risk of ocular events in patients (pts) with relapsed/refractory multiple myeloma (RRMM) from the DREAMM-7 and DREAMM-8 trials of belantamab mafodotin (belamaf).
M. Beksaç, H. Quach, V. Hungria, L. Pour +16 more
2025Journal of Clinical Oncology2 citations
Semantic Scholar
Isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) in newly diagnosed multiple myeloma (NDMM): Outcomes in patients with 1q21+ status in the phase 3 IMROZ study.
M. Dimopoulos, X. Leleu, M. Beksaç, L. Pour +16 more
2025Journal of Clinical Oncology2 citations Open access
Semantic Scholar
An open‐label, first‐in‐human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma
P. Kapoor, N. Nathwani, Tomáš Jelínek, L. Pour +13 more
2024European Journal of Haematology2 citations Open access
Semantic Scholar
OA-13 Belantamab Mafodotin, Pomalidomide, and Dexamethasone vs Pomalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Patient-Reported Outcomes from DREAMM-8
M. Dimopoulos, M. Beksaç, L. Pour, S. Delimpasi +20 more
2024Clinical Lymphoma, Myeloma & Leukemia2 citations
Semantic Scholar
Health-Related Quality of Life (HRQoL) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone: Results from the Imroz Study
M. Dimopoulos, T. Facon, M. Beksaç, L. Pour +25 more
2024Blood2 citations
Semantic Scholar
Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide‐refractory multiple myeloma: Subgroup analysis of the BOSTON trial
S. Delimpasi, I. Špička, J. Butler, Don Stevens +5 more
2026British Journal of Haematology1 citations Open access
Semantic Scholar
B09 | DARATUMUMAB MONOTHERAPY VERSUS ACTIVE MONITORING IN PATIENTS WITH HIGH-RISK SMOLDERING MULTIPLE MYELOMA: "AQUILA" OUTCOMES BASED ON MAYO 2018/IMWG 2020 RISK STRATIFICATION, IMWG 2020 PLUS CYTOGENETIC CRITERIA, AND AGE
F. Schjesvold, P. Voorhees, M. Dimopoulos, Y. Cohen +35 more
2026Haematologica1 citations Open access
Semantic Scholar
Isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study: Effect of body weight on pharmacokinetics and clinical outcome
Jin Lu, A. Oriol, A. Berkovits, Andrew Spencer +21 more
2025Blood1 citations
Semantic Scholar
Efficacy and safety of isatuximab subcutaneous (SC) plus carfilzomib and dexamethasone (Isa-Kd) in patients with relapsed/refractory multiple myeloma (RRMM): Results of the phase 2 study IZALCO.
Gurdeep Parmar, M. Capra, Fernanda Seguro, V. Hungria +14 more
2025Journal of Clinical Oncology1 citations
Semantic Scholar
Isatuximab Subcutaneous (Isa SC) via On-Body Injector (OBI) or Manual Injection for Relapsed/Refractory Multiple Myeloma (RRMM): Patient Experience from the Phase 2 IZALCO Study
Gurdeep Parmar, V. Hungria, M. Dimopoulos, S. Delimpasi +17 more
2025Clinical Lymphoma, Myeloma & Leukemia1 citations
Semantic Scholar
MM-1045: Updated Results From the Phase 3 DREAMM-8 Study of Belantamab Mafodotin (Belamaf) Plus Pomalidomide and Dexamethasone (BPd) vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma
Meletios A. Dimopolous, M. Beksaç, L. Pour, Sosana Delimapsi +17 more
2025Clinical Lymphoma, Myeloma & Leukemia1 citations
Semantic Scholar
Isatuximab (Isa) subcutaneous (SC) via an on-body delivery system (OBDS) vs Isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): Results of the randomized, non-inferiority, phase 3 IRAKLIA study.
S. Ailawadhi, I. Špička, Jin Lu, A. Oriol +16 more
2025Journal of Clinical Oncology1 citations Open access
Semantic Scholar
OA-62 Results From the Randomized Phase 3 DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, Dexamethasone vs Pomalidomide Plus Bortezomib, Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma
Suzanne Trudel, M. Beksaç, L. Pour, S. Delimpasi +19 more
2024Clinical Lymphoma, Myeloma & Leukemia1 citations
Semantic Scholar
P1294: REAL-WORLD OUTCOMES OF 2149 NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS
T. Popková, L. Pour, I. Špička, J. Radocha +12 more
2023HemaSphere1 citations Open access
Semantic Scholar
OA-48 Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed multiple myeloma (IKEMA): final overall survival analysis
K. Yong, T. Martin, M. Dimopoulos, J. Mikhael +17 more
2023Clinical Lymphoma, Myeloma & Leukemia1 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

L. Pour×24
Invite
L. Pour — researcher profile on SciRah
M. Beksaç×22
Invite
M. Beksaç — researcher profile on SciRah
J. Minařík×20
Invite
J. Minařík — researcher profile on SciRah
M. Dimopoulos×17
Invite
M. Dimopoulos — researcher profile on SciRah

×16

Invite

P. Robak — researcher profile on SciRah

Invite

J. Radocha — researcher profile on SciRah

S. Delimpasi×15

Invite

S. Delimpasi — researcher profile on SciRah

Invite

V. Hungria — researcher profile on SciRah

Vladimir I. Vorobyev×13

Invite

Vladimir I. Vorobyev — researcher profile on SciRah

Invite

H. Quach — researcher profile on SciRah

Invite

X. Leleu — researcher profile on SciRah

F. Schjesvold×12

Invite

F. Schjesvold — researcher profile on SciRah